Vosoritide Patent Expiration

Vosoritide is used for promoting linear growth in pediatric patients with achondroplasia. It was first introduced by Biomarin Pharmaceutical Inc in its drug Voxzogo on Nov 19, 2021.


Vosoritide Patents

Given below is the list of patents protecting Vosoritide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Voxzogo US10646550 Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug 01, 2036 Biomarin Pharm
Voxzogo US11590204 Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug 01, 2036 Biomarin Pharm
Voxzogo US11911446 Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug 01, 2036 Biomarin Pharm
Voxzogo US8198242 Variants of C-type natriuretic peptide Jun 11, 2030 Biomarin Pharm
Voxzogo US9907834 Use of C-type natriuretic peptide variants to treat skeletal dysplasia Aug 01, 2036 Biomarin Pharm
Voxzogo USRE48267 Variants of C-type natriuretic peptide May 20, 2030 Biomarin Pharm


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vosoritide's patents.

Given below is the list recent legal activities going on the following patents of Vosoritide.

Event Date Patent/Publication
Patent litigations
transaction for FDA Determination of Regulatory Review Period 04 Mar, 2024 US8198242
transaction for FDA Determination of Regulatory Review Period 28 Feb, 2024 US8198242
Second letter to regulating agency to determine regulatory review period 05 Jan, 2024 US8198242
Payment of Maintenance Fee, 12th Year, Large Entity 21 Nov, 2023 US8198242
Payment of Maintenance Fee, 4th Year, Large Entity 19 Oct, 2023 US10646550
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2023 US8198242
Initial letter Re: PTE Application to regulating agency 03 Aug, 2022 US8198242
Payment of Maintenance Fee, 4th Year, Large Entity 07 Sep, 2021 US9907834
Post Issue Communication - Certificate of Correction 21 Jan, 2021 US10646550
Sequence Moved to Public Database 17 May, 2020 US10646550



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳